{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:05:13Z","timestamp":1789977913909,"version":"4.0.1"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Hypertens Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose of Review<\/jats:title>\n                    <jats:p>Pre-eclampsia remains a leading cause of maternal and perinatal morbidity and mortality worldwide, yet no disease-modifying therapy currently exists. This review examines the challenges inherent in developing therapeutics for pre-eclampsia, and evaluates the evidence for repurposing existing drugs and developing novel biologic strategies to treat preterm pre-eclampsia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>Metformin has demonstrated a trend towards prolongation of pregnancy in a randomized controlled trial, with larger trials ongoing. Proton pump inhibitors and sulfasalazine show compelling preclinical efficacy, though neither has yet translated to clinical benefit, possibly reflecting inadequate drug exposure in vivo. Novel biologic approaches, including sFlt-1-targeting siRNA, complement inhibition with eculizumab, and placenta-tropic lipid nanoparticle delivery systems, represent promising emerging strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Advancing molecular classification of pre-eclampsia is essential to identifying targetable pathways and selecting patients most likely to benefit from specific interventions. Improved pharmacokinetic evaluation in pregnancy, earlier identification of at-risk women using circulating biomarkers, and regulatory frameworks supportive of obstetric research will be critical to translating promising candidates into effective therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11906-026-01392-5","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:21:54Z","timestamp":1789975314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutics Beyond Delivery: Repurposed Drugs and Biologic Pathways"],"prefix":"10.1007","volume":"28","author":[{"given":"Michael","family":"Wilkinson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Myers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"key":"1392_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.preghy.2021.09.008","volume":"27","author":"LA Magee","year":"2022","unstructured":"Magee LA, Brown MA, Hall DR, Gupte S, Hennessy A, Karumanchi SA, et al. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis and management recommendations for international practice. Pregnancy Hypertens. 2022;27:148\u201369. https:\/\/doi.org\/10.1016\/j.preghy.2021.09.008.","journal-title":"Pregnancy Hypertens"},{"key":"1392_CR2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.placenta.2009.02.009","volume":"30","author":"GJ Burton","year":"2009","unstructured":"Burton GJ, Woods AW, Jauniaux E, Kingdom JCP. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009;30:473\u201382. https:\/\/doi.org\/10.1016\/j.placenta.2009.02.009.","journal-title":"Placenta"},{"key":"1392_CR3","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1056\/NEJMoa031884","volume":"350","author":"RJ Levine","year":"2004","unstructured":"Levine RJ, Maynard SE, Qian C, Lim K-H, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672\u201383. https:\/\/doi.org\/10.1056\/NEJMoa031884.","journal-title":"N Engl J Med"},{"key":"1392_CR4","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1080\/14767058.2016.1185411","volume":"30","author":"RO Bahado-Singh","year":"2017","unstructured":"Bahado-Singh RO, Syngelaki A, Mandal R, Graham SF, Akolekar R, Han B, et al. Metabolomic determination of pathogenesis of late-onset preeclampsia. J Matern Fetal Neonatal Med. 2017;30:658\u201364. https:\/\/doi.org\/10.1080\/14767058.2016.1185411.","journal-title":"J Matern Fetal Neonatal Med"},{"key":"1392_CR5","doi-asserted-by":"publisher","first-page":"Se91","DOI":"10.1016\/j.ajog.2015.08.003","volume":"213","author":"CWG Redman","year":"2015","unstructured":"Redman CWG, Staff AC. Preeclampsia, biomarkers, syncytiotrophoblast stress, and placental capacity. Am J Obstet Gynecol. 2015;213:Se91\u20134. https:\/\/doi.org\/10.1016\/j.ajog.2015.08.003","journal-title":"Am J Obstet Gynecol"},{"key":"1392_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1515\/jpm-2022-0433","volume":"51","author":"NG Than","year":"2023","unstructured":"Than NG, Romero R, Gy\u00f6rffy D, Posta M, Bhatti G, Done B, et al. Molecular subclasses of preeclampsia characterized by a longitudinal maternal proteomics study: distinct biomarkers, disease pathways and options for prevention. J Perinat Med. 2023;51:51\u201368. https:\/\/doi.org\/10.1515\/jpm-2022-0433.","journal-title":"J Perinat Med"},{"key":"1392_CR7","doi-asserted-by":"publisher","first-page":"n2103","DOI":"10.1136\/bmj.n2103","volume":"374","author":"CA Cluver","year":"2021","unstructured":"Cluver CA, Hiscock R, Decloedt EH, Hall DR, Schell S, Mol BW, et al. Use of metformin to prolong gestation in preterm pre-eclampsia: randomised, double blind, placebo controlled trial. BMJ. 2021;374:n2103. https:\/\/doi.org\/10.1136\/bmj.n2103.","journal-title":"BMJ"},{"key":"1392_CR8","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s43441-022-00433-w","volume":"56","author":"AL David","year":"2022","unstructured":"David AL, Ahmadzia H, Ashcroft R, Bucci-Rechtweg C, Spencer RN, Thornton S. Improving development of drug treatments for pregnant women and the fetus. Ther Innov Regul Sci. 2022;56:976\u201390. https:\/\/doi.org\/10.1007\/s43441-022-00433-w.","journal-title":"Ther Innov Regul Sci"},{"key":"1392_CR9","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ogrm.2019.04.011","volume":"29","author":"A Sharp","year":"2019","unstructured":"Sharp A, Cornforth C, Alfirevic Z. Learning from the STRIDER trial. Obstet Gynaecol Reprod Med. 2019;29:240\u20131. https:\/\/doi.org\/10.1016\/j.ogrm.2019.04.011.","journal-title":"Obstet Gynaecol Reprod Med"},{"key":"1392_CR10","doi-asserted-by":"publisher","first-page":"e70523","DOI":"10.1111\/liv.70523","volume":"46","author":"C Ovadia","year":"2026","unstructured":"Ovadia C, Stone S, Sibai B, Nunes T, Mogul DB, Krishnaswami J, et al. Efficacy, safety and tolerability of volixibat, an IBAT inhibitor, in patients with intrahepatic cholestasis of pregnancy. Liver Int. 2026;46:e70523. https:\/\/doi.org\/10.1111\/liv.70523.","journal-title":"Liver Int"},{"key":"1392_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jri.2007.03.011","volume":"76","author":"KR Rosenberg","year":"2007","unstructured":"Rosenberg KR, Trevathan WR. An anthropological perspective on the evolutionary context of preeclampsia in humans. J Reprod Immunol. 2007;76:91\u20137. https:\/\/doi.org\/10.1016\/j.jri.2007.03.011.","journal-title":"J Reprod Immunol"},{"key":"1392_CR12","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1161\/HYPERTENSIONAHA.119.14598","volume":"75","author":"KL Gatford","year":"2020","unstructured":"Gatford KL, Andraweera PH, Roberts CT, Care AS. Animal models of preeclampsia: causes, consequences, and interventions. Hypertension. 2020;75:1363\u201381. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14598.","journal-title":"Hypertension"},{"key":"1392_CR13","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.bpobgyn.2008.06.005","volume":"22","author":"A Carlin","year":"2008","unstructured":"Carlin A, Alfirevic Z. Physiological changes of pregnancy and monitoring. Best Pract Res Clin Obstet Gynaecol. 2008;22:801\u201323. . https:\/\/doi.org\/10.1016\/j.bpobgyn.2008.06.005","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"1392_CR14","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1002\/uog.18835","volume":"52","author":"D Stott","year":"2018","unstructured":"Stott D, Nzelu O, Nicolaides KH, Kametas NA. Maternal hemodynamics in normal pregnancy and in pregnancy affected by pre-eclampsia. Ultrasound Obstet Gynecol. 2018;52:359\u201364. https:\/\/doi.org\/10.1002\/uog.18835.","journal-title":"Ultrasound Obstet Gynecol"},{"key":"1392_CR15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1124\/dmd.112.046276","volume":"41","author":"SY Choi","year":"2013","unstructured":"Choi SY, Koh KH, Jeong H. Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013;41:263\u20139. https:\/\/doi.org\/10.1124\/dmd.112.046276.","journal-title":"Drug Metab Dispos"},{"key":"1392_CR16","doi-asserted-by":"publisher","first-page":"487","DOI":"10.2165\/00003088-200443080-00001","volume":"43","author":"MR Syme","year":"2004","unstructured":"Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004;43:487\u2013514. https:\/\/doi.org\/10.2165\/00003088-200443080-00001.","journal-title":"Clin Pharmacokinet"},{"key":"1392_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3390\/antib15010014","volume":"15","author":"Q Li","year":"2026","unstructured":"Li Q, Huang Z, Saeed Z, Greer O, Harker JA, Shah NM. Transplacental antibody transfer: mechanisms, pregnancy-related disruptions, and emerging experimental models. Antibodies. 2026;15:14. https:\/\/doi.org\/10.3390\/antib15010014.","journal-title":"Antibodies"},{"key":"1392_CR18","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/978-1-4939-7498-6_14","volume":"1710","author":"P Brownbill","year":"2018","unstructured":"Brownbill P, Sebire N, McGillick EV, Ellery S, Murthi P. Ex vivo dual perfusion of the human placenta: disease simulation, therapeutic pharmacokinetics and analysis of off-target effects. Methods Mol Biol. 2018;1710:173\u201389. https:\/\/doi.org\/10.1007\/978-1-4939-7498-6_14.","journal-title":"Methods Mol Biol"},{"key":"1392_CR19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1111\/j.1365-2125.2012.04363.x","volume":"74","author":"L Gaohua","year":"2012","unstructured":"Gaohua L, Abduljalil K, Jamei M, Johnson TN, Rostami-Hodjegan A. A pregnancy physiologically based pharmacokinetic (p-PBPK) model for disposition of drugs metabolized by CYP1A2, CYP2D6 and CYP3A4. Br J Clin Pharmacol. 2012;74:873\u201385. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04363.x.","journal-title":"Br J Clin Pharmacol"},{"key":"1392_CR20","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2352-4642(17)30173-6","volume":"2","author":"A Sharp","year":"2018","unstructured":"Sharp A, Cornforth C, Jackson R, Harrold J, Turner MA, Kenny LC, et al. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. Lancet Child Adolesc Health. 2018;2:93\u2013102. https:\/\/doi.org\/10.1016\/S2352-4642(17)30173-6.","journal-title":"Lancet Child Adolesc Health"},{"key":"1392_CR21","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ajog.2020.01.025","volume":"222","author":"J Turner","year":"2020","unstructured":"Turner J, Dunn L, Tarnow-Mordi W, Flatley C, Flenady V, Kumar S. Safety and efficacy of sildenafil citrate to reduce operative birth for intrapartum fetal compromise at term: a phase 2 randomized controlled trial. Am J Obstet Gynecol. 2020;222:401\u201314. https:\/\/doi.org\/10.1016\/j.ajog.2020.01.025.","journal-title":"Am J Obstet Gynecol"},{"key":"1392_CR22","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/S2352-4642(18)30114-7","volume":"2","author":"F Terstappen","year":"2018","unstructured":"Terstappen F, Paauw ND, Joles JA, Gremmels H, Lely AT. No improvement of pregnancy outcomes in first STRIDER trial: result of a low dose? Lancet Child Adolesc Health. 2018;2:e11. https:\/\/doi.org\/10.1016\/S2352-4642(18)30114-7.","journal-title":"Lancet Child Adolesc Health"},{"key":"1392_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1056\/NEJMoa1704559","volume":"377","author":"DL Rolnik","year":"2017","unstructured":"Rolnik DL, Wright D, Poon LC, O\u2019Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med. 2017;377:613\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1704559.","journal-title":"N Engl J Med"},{"key":"1392_CR24","doi-asserted-by":"publisher","first-page":"101260","DOI":"10.1016\/j.ajogmf.2023.101260","volume":"6","author":"H Provinciatto","year":"2024","unstructured":"Provinciatto H, Barbalho ME, Almeida J, Provinciatto A, Philip CE. The role of pravastatin in preventing preeclampsia in high-risk pregnant women: a meta-analysis with trial sequential analysis. Am J Obstet Gynecol MFM. 2024;6:101260. https:\/\/doi.org\/10.1016\/j.ajogmf.2023.101260.","journal-title":"Am J Obstet Gynecol MFM"},{"key":"1392_CR25","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1016\/S0140-6736(16)31139-4","volume":"388","author":"MA Rodger","year":"2016","unstructured":"Rodger MA, Gris JC, de Vries JIP, Martinelli I, Rey \u00c9, Schleussner E, et al. Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials. Lancet. 2016;388:2629\u201341. https:\/\/doi.org\/10.1016\/S0140-6736(16)31139-4.","journal-title":"Lancet"},{"key":"1392_CR26","doi-asserted-by":"publisher","first-page":"485","DOI":"10.3390\/jcm12020485","volume":"12","author":"Z Hu","year":"2023","unstructured":"Hu Z, Gao R, Huang W, Wang H, Qin L. Effect of hydroxychloroquine on lupus activity, preeclampsia and intrauterine growth restriction in pregnant women with systemic lupus erythematosus and\/or antiphospholipid syndrome: a systematic review and meta-analysis. J Clin Med. 2023;12:485. https:\/\/doi.org\/10.3390\/jcm12020485.","journal-title":"J Clin Med"},{"key":"1392_CR27","doi-asserted-by":"publisher","first-page":"e02242","DOI":"10.7554\/eLife.02242","volume":"3","author":"WW Wheaton","year":"2014","unstructured":"Wheaton WW, Weinberg SE, Hamanaka RB, Soberanes S, Sullivan LB, Anso E, et al. Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis. Elife. 2014;3:e02242. https:\/\/doi.org\/10.7554\/eLife.02242.","journal-title":"Elife"},{"key":"1392_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/2049-3002-2-12","volume":"2","author":"S Andrzejewski","year":"2014","unstructured":"Andrzejewski S, Gravel S-P, Pollak M, St-Pierre J. Metformin directly acts on mitochondria to alter cellular bioenergetics. Cancer Metab. 2014;2:12. https:\/\/doi.org\/10.1186\/2049-3002-2-12.","journal-title":"Cancer Metab"},{"key":"1392_CR29","doi-asserted-by":"publisher","first-page":"e3561","DOI":"10.1016\/j.ajog.2015.12.019","volume":"214","author":"FC Brownfoot","year":"2016","unstructured":"Brownfoot FC, Hastie R, Hannan NJ, Cannon P, Tuohey L, Parry LJ, et al. Metformin as a prevention and treatment for preeclampsia: effects on soluble fms-like tyrosine kinase 1 and soluble endoglin secretion and endothelial dysfunction. Am J Obstet Gynecol. 2016;214:e3561\u201335615. https:\/\/doi.org\/10.1016\/j.ajog.2015.12.019.","journal-title":"Am J Obstet Gynecol"},{"key":"1392_CR30","doi-asserted-by":"publisher","first-page":"e082880","DOI":"10.1136\/bmjopen-2023-082880","volume":"14","author":"CA Cluver","year":"2024","unstructured":"Cluver CA, Bergman L, Imberg H, Mol BW, Hall D, Bekker A, et al. Does metformin prolong pregnancy in preterm pre-eclampsia? A study protocol for a South African, hospital-based double-blind, randomised, placebo-controlled trial. BMJ Open. 2024;14:e082880. https:\/\/doi.org\/10.1136\/bmjopen-2023-082880.","journal-title":"BMJ Open"},{"key":"1392_CR31","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/ajg.2009.122","volume":"104","author":"SK Gill","year":"2009","unstructured":"Gill SK, O\u2019Brien L, Einarson TR, Koren G. The safety of proton pump inhibitors (PPIs) in pregnancy: a meta-analysis. Am J Gastroenterol. 2009;104:1541\u20135. https:\/\/doi.org\/10.1038\/ajg.2009.122.","journal-title":"Am J Gastroenterol"},{"key":"1392_CR32","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1161\/HYPERTENSIONAHA.116.08408","volume":"69","author":"K Onda","year":"2017","unstructured":"Onda K, Tong S, Beard S, Binder N, Muto M, Senadheera SN, et al. Proton pump inhibitors decrease soluble fms-like tyrosine kinase-1 and soluble endoglin secretion, decrease hypertension, and rescue endothelial dysfunction. Hypertension. 2017;69:457\u201368. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08408.","journal-title":"Hypertension"},{"key":"1392_CR33","doi-asserted-by":"publisher","first-page":"7407","DOI":"10.3390\/ijms22147407","volume":"22","author":"Y Sun","year":"2021","unstructured":"Sun Y, Tan L, Neuman RI, Broekhuizen M, Schoenmakers S, Lu X, et al. Megalin, proton pump inhibitors and the renin\u2013angiotensin system in healthy and pre-eclamptic placentas. Int J Mol Sci. 2021;22:7407. https:\/\/doi.org\/10.3390\/ijms22147407.","journal-title":"Int J Mol Sci"},{"key":"1392_CR34","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1161\/HYPERTENSIONAHA.118.12547","volume":"73","author":"R Hastie","year":"2019","unstructured":"Hastie R, Bergman L, Cluver CA, Wikman A, Hannan NJ, Walker SP, et al. Proton pump inhibitors and preeclampsia risk among 157 720 women. Hypertension. 2019;73:1097\u2013103. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.118.12547.","journal-title":"Hypertension"},{"key":"1392_CR35","doi-asserted-by":"publisher","first-page":"4675","DOI":"10.3390\/jcm11164675","volume":"11","author":"S Hussain","year":"2022","unstructured":"Hussain S, Singh A, Antony B, Klugarov\u00e1 J, Murad MH, Jayraj AS, et al. Proton pump inhibitors use and risk of preeclampsia: a meta-analysis. J Clin Med. 2022;11:4675. https:\/\/doi.org\/10.3390\/jcm11164675.","journal-title":"J Clin Med"},{"key":"1392_CR36","doi-asserted-by":"publisher","first-page":"e3881","DOI":"10.1016\/j.ajog.2018.07.019","volume":"219","author":"CA Cluver","year":"2018","unstructured":"Cluver CA, Hannan NJ, van Papendorp E, Hiscock R, Beard S, Mol BW, et al. Esomeprazole to treat women with preterm preeclampsia: a randomized placebo controlled trial. Am J Obstet Gynecol. 2018;219:e3881\u201338817. https:\/\/doi.org\/10.1016\/j.ajog.2018.07.019.","journal-title":"Am J Obstet Gynecol"},{"key":"1392_CR37","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1161\/HYPERTENSIONAHA.122.19070","volume":"79","author":"RI Neuman","year":"2022","unstructured":"Neuman RI, Baars MD, Saleh L, Broekhuizen M, Nieboer D, Cornette J, et al. Omeprazole administration in preterm preeclampsia: a randomized controlled trial to study its effect on sFlt-1 (soluble fms-like tyrosine kinase-1), PlGF (placental growth factor), and ET-1 (endothelin-1). Hypertension. 2022;79:1297\u2013307. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.122.19070.","journal-title":"Hypertension"},{"key":"1392_CR38","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.1016\/S0140-6736(18)33212-4","volume":"393","author":"KE Duhig","year":"2019","unstructured":"Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, et al. Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial. Lancet. 2019;393:1807\u201318. https:\/\/doi.org\/10.1016\/S0140-6736(18)33212-4.","journal-title":"Lancet"},{"key":"1392_CR39","doi-asserted-by":"publisher","first-page":"3864941","DOI":"10.1155\/2020\/3864941","volume":"2020","author":"M Michalczyk","year":"2020","unstructured":"Michalczyk M, Celewicz A, Celewicz M, Wozniakowska-Gondek P, Rzepka R. The role of inflammation in the pathogenesis of preeclampsia. Mediators Inflamm. 2020;2020:3864941. https:\/\/doi.org\/10.1155\/2020\/3864941.","journal-title":"Mediators Inflamm"},{"key":"1392_CR40","doi-asserted-by":"publisher","first-page":"1009867","DOI":"10.3389\/fimmu.2023.1009867","volume":"14","author":"X Wei","year":"2023","unstructured":"Wei X, Yang X. The central role of natural killer cells in preeclampsia. Front Immunol. 2023;14:1009867. https:\/\/doi.org\/10.3389\/fimmu.2023.1009867.","journal-title":"Front Immunol"},{"key":"1392_CR41","doi-asserted-by":"publisher","first-page":"6649608","DOI":"10.1155\/2021\/6649608","volume":"2021","author":"T Spence","year":"2021","unstructured":"Spence T, Allsopp PJ, Yeates AJ, Mulhern MS, Strain JJ, McSorley EM. Maternal serum cytokine concentrations in healthy pregnancy and preeclampsia. J Pregnancy. 2021;2021:6649608. https:\/\/doi.org\/10.1155\/2021\/6649608.","journal-title":"J Pregnancy"},{"key":"1392_CR42","doi-asserted-by":"publisher","first-page":"108939","DOI":"10.1016\/j.reprotox.2025.108939","volume":"135","author":"R Asthana","year":"2025","unstructured":"Asthana R, Hamandi B, Brnabic A, Papadimitropoulos E, Piquette-Miller M. Meta-analysis and systematic review on sulfasalazine\/5-ASA use during pregnancy: impact on neonatal and pregnancy outcomes. Reprod Toxicol. 2025;135:108939. https:\/\/doi.org\/10.1016\/j.reprotox.2025.108939.","journal-title":"Reprod Toxicol"},{"issue":"Suppl 2","key":"1392_CR43","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/rheumatology\/XXXIV.suppl_2.7","volume":"34","author":"G Smedeg\u00e5rd","year":"1995","unstructured":"Smedeg\u00e5rd G, Bj\u00f6rk J. Sulphasalazine: mechanism of action in rheumatoid arthritis. Br J Rheumatol. 1995;34(Suppl 2):7\u201315. https:\/\/doi.org\/10.1093\/rheumatology\/XXXIV.suppl_2.7.","journal-title":"Br J Rheumatol"},{"key":"1392_CR44","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ebiom.2019.02.013","volume":"41","author":"FC Brownfoot","year":"2019","unstructured":"Brownfoot FC, Hannan NJ, Cannon P, Nguyen V, Hastie R, Parry LJ, et al. Sulfasalazine reduces placental secretion of antiangiogenic factors, up-regulates the secretion of placental growth factor and rescues endothelial dysfunction. EBioMedicine. 2019;41:636\u201348. https:\/\/doi.org\/10.1016\/j.ebiom.2019.02.013.","journal-title":"EBioMedicine"},{"key":"1392_CR45","doi-asserted-by":"publisher","first-page":"103779","DOI":"10.1016\/j.eclinm.2026.103779","volume":"92","author":"E Kadife","year":"2026","unstructured":"Kadife E, Decloedt E, Louw V, Abdulla ZB, Kellermann T, Pillay-Fuentes Lorente V, et al. Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial. EClinicalMedicine. 2026;92:103779. https:\/\/doi.org\/10.1016\/j.eclinm.2026.103779.","journal-title":"EClinicalMedicine"},{"key":"1392_CR46","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1111\/1471-0528.17093","volume":"129","author":"LJ O\u2019Byrne","year":"2022","unstructured":"O\u2019Byrne LJ, Alqatari SG, Maher GM, O\u2019Sullivan AM, Khashan AS, Murphy GP, et al. Fetal and maternal outcomes after maternal biologic use during conception and pregnancy: a systematic review and meta-analysis. BJOG. 2022;129:1236\u201346. https:\/\/doi.org\/10.1111\/1471-0528.17093.","journal-title":"BJOG"},{"key":"1392_CR47","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/s44222-023-00064-2","volume":"1","author":"K Zhang","year":"2023","unstructured":"Zhang K, Cheng K. Stem cell-derived exosome versus stem cell therapy. Nat Rev Bioeng. 2023;1:608\u20139. https:\/\/doi.org\/10.1038\/s44222-023-00064-2.","journal-title":"Nat Rev Bioeng"},{"key":"1392_CR48","doi-asserted-by":"publisher","first-page":"105834","DOI":"10.1016\/j.ebiom.2025.105834","volume":"118","author":"G Geng","year":"2025","unstructured":"Geng G, Xu Y, Hu Z, Wang H, Chen X, Yuan W et al. Viral and non-viral vectors in gene therapy: current state and clinical perspectives. EBioMedicine. Elsevier B.V. 2025;118:105834. https:\/\/doi.org\/10.1016\/j.ebiom.2025.105834","journal-title":"EBioMedicine"},{"key":"1392_CR49","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10:210. https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther"},{"key":"1392_CR50","doi-asserted-by":"publisher","first-page":"8316","DOI":"10.1039\/D4NR05338A","volume":"17","author":"L Wang","year":"2025","unstructured":"Wang L, Mu Q, Zhang W, Zheng W, Zhu X, Yu Y, et al. Placental targeted drug delivery: a review of recent progress. Nanoscale. 2025;17:8316\u201335. https:\/\/doi.org\/10.1039\/D4NR05338A.","journal-title":"Nanoscale"},{"key":"1392_CR51","doi-asserted-by":"publisher","first-page":"10382","DOI":"10.1074\/jbc.M313237200","volume":"279","author":"HW Christinger","year":"2004","unstructured":"Christinger HW, Fuh G, De Vos AM, Wiesmann C. The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1. J Biol Chem. 2004;279:10382\u20138. https:\/\/doi.org\/10.1074\/jbc.M313237200.","journal-title":"J Biol Chem"},{"key":"1392_CR52","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa1414838","volume":"374","author":"H Zeisler","year":"2016","unstructured":"Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstr\u00f6m M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med. 2016;374:13\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1414838.","journal-title":"N Engl J Med"},{"key":"1392_CR53","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.3390\/ijms26114992","volume":"26","author":"A Callan","year":"2025","unstructured":"Callan A, Heckman J, Tah G, Lopez S, Valdez L, Tsin A. VEGF in diabetic retinopathy and age-related macular degeneration. Int J Mol Sci. 2025;26:4992. https:\/\/doi.org\/10.3390\/ijms26114992.","journal-title":"Int J Mol Sci"},{"key":"1392_CR54","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ctrv.2011.12.008","volume":"38","author":"A Gaya","year":"2012","unstructured":"Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012;38:484\u201393. https:\/\/doi.org\/10.1016\/j.ctrv.2011.12.008.","journal-title":"Cancer Treat Rev"},{"key":"1392_CR55","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/nature05249","volume":"443","author":"BK Ambati","year":"2006","unstructured":"Ambati BK, Nozaki M, Singh N, Takeda A, Jani PD, Suthar T, et al. Corneal avascularity is due to soluble VEGF receptor-1. Nature. 2006;443:993\u20137. https:\/\/doi.org\/10.1038\/nature05249.","journal-title":"Nature"},{"key":"1392_CR56","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.3390\/ijms26083456","volume":"26","author":"O Ebenezer","year":"2025","unstructured":"Ebenezer O, Oyebamiji AK, Olanlokun JO, Tuszynski JA, Wong GKS. Recent update on siRNA therapeutics. Int J Mol Sci. 2025;26:3456. https:\/\/doi.org\/10.3390\/ijms26083456.","journal-title":"Int J Mol Sci"},{"key":"1392_CR57","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/nbt.4297","volume":"36","author":"AA Turanov","year":"2018","unstructured":"Turanov AA, Lo A, Hassler MR, Makris A, Ashar-Patel A, Alterman JF, et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat Biotechnol. 2018;36:1164\u201373. https:\/\/doi.org\/10.1038\/nbt.4297.","journal-title":"Nat Biotechnol"},{"key":"1392_CR58","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/molehr\/gaw077","volume":"23","author":"KR Palmer","year":"2017","unstructured":"Palmer KR, Tong S, Kaitu\u2019u-Lino TJ. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. Mol Hum Reprod. 2017;23:69\u201378. https:\/\/doi.org\/10.1093\/molehr\/gaw077.","journal-title":"Mol Hum Reprod"},{"key":"1392_CR59","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0140-6736(20)32335-7","volume":"398","author":"LC Chappell","year":"2021","unstructured":"Chappell LC, Cluver CA, Kingdom J, Tong S, Pre-eclampsia. Lancet. 2021;398:341\u201354. https:\/\/doi.org\/10.1016\/S0140-6736(20)32335-7.","journal-title":"Lancet"},{"key":"1392_CR60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s11906-017-0784-4","volume":"19","author":"JF Regal","year":"2017","unstructured":"Regal JF, Burwick RM, Fleming SD. The complement system and preeclampsia. Curr Hypertens Rep. 2017;19:87. https:\/\/doi.org\/10.1007\/s11906-017-0784-4.","journal-title":"Curr Hypertens Rep"},{"key":"1392_CR61","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1161\/HYPERTENSIONAHA.113.01420","volume":"62","author":"RM Burwick","year":"2013","unstructured":"Burwick RM, Fichorova RN, Dawood HY, Yamamoto HS, Feinberg BB. Urinary excretion of C5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013;62:1040\u20135. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01420.","journal-title":"Hypertension"},{"key":"1392_CR62","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/AOG.0000000000002980","volume":"132","author":"RM Burwick","year":"2018","unstructured":"Burwick RM, Vel\u00e1squez JA, Valencia CM, Guti\u00e9rrez-Mar\u00edn J, Edna-Estrada F, Silva JL, et al. Terminal complement activation in preeclampsia. Obstet Gynecol. 2018;132:1477\u201385. https:\/\/doi.org\/10.1097\/AOG.0000000000002980.","journal-title":"Obstet Gynecol"},{"key":"1392_CR63","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic\u2013uremic syndrome. N Engl J Med. 2009;361:1676\u201387. https:\/\/doi.org\/10.1056\/NEJMra0902814.","journal-title":"N Engl J Med"},{"key":"1392_CR64","doi-asserted-by":"publisher","first-page":"101392","DOI":"10.1016\/j.lanepe.2025.101392","volume":"56","author":"A Bryant","year":"2025","unstructured":"Bryant A, Lecouturier J, Orozco-Leal G, Brocklebank V, Carnell S, Chadwick T, et al. Eculizumab withdrawal and monitoring in atypical haemolytic uraemic syndrome (SETS aHUS): a multicentre, open label, prospective, single arm trial. Lancet Reg Health Eur. 2025;56:101392. https:\/\/doi.org\/10.1016\/j.lanepe.2025.101392.","journal-title":"Lancet Reg Health Eur"},{"key":"1392_CR65","doi-asserted-by":"publisher","first-page":"3304","DOI":"10.1182\/bloodadvances.2024014746","volume":"9","author":"GF Gerber","year":"2025","unstructured":"Gerber GF, Brodsky RA, Vaught AJ. Complement C5 inhibition in early onset HELLP syndrome. Blood Adv. 2025;9:3304\u20137. https:\/\/doi.org\/10.1182\/bloodadvances.2024014746.","journal-title":"Blood Adv"},{"key":"1392_CR66","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","volume":"76","author":"NRH Stone","year":"2016","unstructured":"Stone NRH, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome\u00ae): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76:485\u2013500. https:\/\/doi.org\/10.1007\/s40265-016-0538-7.","journal-title":"Drugs"},{"key":"1392_CR67","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.copbio.2004.10.005","volume":"15","author":"D Felnerova","year":"2004","unstructured":"Felnerova D, Viret JF, Gl\u00fcck R, Moser C. Liposomes and virosomes as delivery systems for antigens, nucleic acids and drugs. Curr Opin Biotechnol. 2004;15:518\u201329. https:\/\/doi.org\/10.1016\/j.copbio.2004.10.005.","journal-title":"Curr Opin Biotechnol"},{"key":"1392_CR68","doi-asserted-by":"publisher","first-page":"103553","DOI":"10.1016\/j.jddst.2022.103553","volume":"74","author":"B Wilson","year":"2022","unstructured":"Wilson B, Geetha KM. Lipid nanoparticles in the development of mRNA vaccines for COVID-19. J Drug Deliv Sci Technol. 2022;74:103553. https:\/\/doi.org\/10.1016\/j.jddst.2022.103553.","journal-title":"J Drug Deliv Sci Technol"},{"key":"1392_CR69","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41586-024-08291-2","volume":"637","author":"KL Swingle","year":"2025","unstructured":"Swingle KL, Hamilton AG, Safford HC, Geisler HC, Thatte AS, Palanki R, et al. Placenta-tropic VEGF mRNA lipid nanoparticles ameliorate murine pre-eclampsia. Nature. 2025;637:412\u201321. https:\/\/doi.org\/10.1038\/s41586-024-08291-2.","journal-title":"Nature"},{"key":"1392_CR70","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc A, Maier MA, Manoharan M, Fitzgerald K, Jayaraman M, Barros S, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14:1084\u20137. https:\/\/doi.org\/10.1038\/s41565-019-0591-y.","journal-title":"Nat Nanotechnol"},{"key":"1392_CR71","doi-asserted-by":"publisher","first-page":"S44","DOI":"10.1016\/j.placenta.2017.09.011","volume":"59","author":"AL David","year":"2017","unstructured":"David AL. Maternal uterine artery VEGF gene therapy for treatment of intrauterine growth restriction. Placenta. 2017;59:S44\u201350. https:\/\/doi.org\/10.1016\/j.placenta.2017.09.011.","journal-title":"Placenta"},{"key":"1392_CR72","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1016\/j.ymthe.2022.04.004","volume":"30","author":"RE Young","year":"2022","unstructured":"Young RE, Hofbauer SI, Riley RS. Overcoming the challenge of long-term storage of mRNA-lipid nanoparticle vaccines. Mol Ther. 2022;30:1792. https:\/\/doi.org\/10.1016\/j.ymthe.2022.04.004.","journal-title":"Mol Ther"},{"key":"1392_CR73","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/1477-7827-7-79","volume":"7","author":"G Valdes","year":"2009","unstructured":"Valdes G, Kaufmann P, Corthorn J, Erices R, Brosnihan KB, Joyner-Grantham JN. Vasodilator factors in the systemic and local adaptations to pregnancy. Reprod Biol Endocrinol. 2009;7:79. https:\/\/doi.org\/10.1186\/1477-7827-7-79.","journal-title":"Reprod Biol Endocrinol"},{"key":"1392_CR74","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1038\/nm0901-1003","volume":"7","author":"S AbdAlla","year":"2001","unstructured":"AbdAlla S, Lother H, El Massiery A, Quitterer U. Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. Nat Med. 2001;7:1003\u20139. https:\/\/doi.org\/10.1038\/nm0901-1003.","journal-title":"Nat Med"},{"key":"1392_CR75","doi-asserted-by":"publisher","first-page":"e104035","DOI":"10.1136\/bmjopen-2025-104035","volume":"15","author":"CA Cluver","year":"2025","unstructured":"Cluver CA, Thake J, Hassim T, Van Greunen A, Budhram S, Knipe K, et al. Safety and potential efficacy of DM199, a tissue kallikrein-1 analogue, for treating pre-eclampsia and fetal growth restriction: study protocol for a South African, hospital-based phase I\/II open-label trial. BMJ Open. 2025;15:e104035. https:\/\/doi.org\/10.1136\/bmjopen-2025-104035.","journal-title":"BMJ Open"},{"key":"1392_CR76","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/cvr\/cvn223","volume":"80","author":"YY Yao","year":"2008","unstructured":"Yao YY, Yin H, Shen B, Smith RS, Liu Y, Gao L, et al. Tissue kallikrein promotes neovascularization and improves cardiac function by the Akt-glycogen synthase kinase-3\u03b2 pathway. Cardiovasc Res. 2008;80:354\u201364. https:\/\/doi.org\/10.1093\/cvr\/cvn223.","journal-title":"Cardiovasc Res"},{"key":"1392_CR77","doi-asserted-by":"publisher","first-page":"E681","DOI":"10.1152\/ajpendo.1988.254.6.E681","volume":"254","author":"BM Wilkes","year":"1988","unstructured":"Wilkes BM, Mento PF. Bradykinin-induced vasoconstriction and thromboxane release in perfused human placenta. Am J Physiol. 1988;254:E681. https:\/\/doi.org\/10.1152\/ajpendo.1988.254.6.E681.","journal-title":"Am J Physiol"},{"key":"1392_CR78","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1203\/00006450-199904010-00017","volume":"45","author":"EAJ Bateson","year":"1999","unstructured":"Bateson EAJ, Schulz R, Olley PM. Response of fetal rabbit ductus arteriosus to bradykinin: role of nitric oxide, prostaglandins, and bradykinin receptors. Pediatr Res. 1999;45:568\u201374. https:\/\/doi.org\/10.1203\/00006450-199904010-00017.","journal-title":"Pediatr Res"}],"container-title":["Current Hypertension Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01392-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11906-026-01392-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11906-026-01392-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T07:21:55Z","timestamp":1789975315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11906-026-01392-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":78,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1392"],"URL":"https:\/\/doi.org\/10.1007\/s11906-026-01392-5","relation":{},"ISSN":["1534-3111"],"issn-type":[{"value":"1534-3111","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]},"assertion":[{"value":"29 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":1,"name":"Ethics","label":"Human and Animal Rights","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"MW has no conflict of interest to disclose. JM is a scientific advisor for Comanche Biopharma.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"JM is a scientific advisor for Comanche Biopharma.","order":3,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"43"}}